Abstract
In this issue of Science Translational Medicine, Wallin et al. have identified a subset of breast and ovarian cancer cell lines that show synergistic response to the combination of doxorubicin and GDC-0941, a class IA phosphatidylinositol 3-kinase (PI3K) inhibitor. Here, we discuss the potential implications of these data on the clinical development of PI3K pathway inhibitors as cancer therapeutics.
Publication types
-
Research Support, N.I.H., Extramural
-
Comment
MeSH terms
-
Antibiotics, Antineoplastic / pharmacology*
-
Antibiotics, Antineoplastic / therapeutic use
-
Biomarkers, Tumor
-
Cell Line, Tumor / drug effects*
-
Doxorubicin / pharmacology*
-
Doxorubicin / therapeutic use
-
Drug Synergism
-
Humans
-
Indazoles / pharmacology*
-
Indazoles / therapeutic use
-
Neoplasms / drug therapy
-
Neoplasms / physiopathology*
-
Phosphoinositide-3 Kinase Inhibitors
-
Sulfonamides / pharmacology*
-
Sulfonamides / therapeutic use
Substances
-
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
-
Antibiotics, Antineoplastic
-
Biomarkers, Tumor
-
Indazoles
-
Phosphoinositide-3 Kinase Inhibitors
-
Sulfonamides
-
Doxorubicin